Share this article on:

Metastatic Neuroendocrine Carcinoma Presenting as a “Superscan” on 68Ga-DOTANOC Somatostatin Receptor PET/CT

Naswa, Niraj; Karunanithi, Sellam; Soundararajan, Ramya; Das, Kalpa Jyoti; Agarwal, Krishan Kant; Malhotra, Arun; Bal, Chandrasekhar; Kumar, Rakesh MD

doi: 10.1097/RLU.0b013e31825b1e6c
Interesting Images

PET/CT imaging using 68Ga-labeled somatostatin analogs has become a popular noninvasive diagnostic modality in the workup of patients with neuroendocrine tumors. A 65-year-old man with pancreatic neuroendocrine tumor with confirmed liver metastases on conventional imaging underwent restaging 68Ga-DOTANOC PET/CT to monitor response to cold octreotide therapy. Previous PET/CT had shown presence of multiple liver and skeletal metastases along with a primary pancreatic tumor showing intense tracer uptake. The present PET/CT study showed an increase in number and uptake of the metastatic lesions suggestive of progressive disease resulting in the appearance of a superscan.

From the Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India.

Received for publication December 17, 2011; revision accepted April 12, 2012.

Conflicts of interest and sources of funding: none declared.

Reprints: Rakesh Kumar, MD, Department of Nuclear Medicine, All India Institute of Medical Sciences, Ansari Nagar, New Delhi-110029, Indica. E-mail:





Back to Top | Article Outline


1. Lamberts SWJ, Krenning E, Reubi JC. The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocrinol Rev. 1991: 12: 450–482.
    2. Bombardieri E, Ambrosini V, Aktolun C, et al.. 111In-pentetreotide scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging. 2010; 37: 1441–1448.
      3. Virgolini I, Ambrosini V, Bomanji JB, et al.. Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging. 2010; 37: 2004–2010.
        4. Haug AR, Rominger A, Mustafa M, et al.. Treatment with octreotide does not reduce tumor uptake of 68Ga-DOTATATE as measured by PET/CT in patients with neuroendocrine tumors. J Nucl Med. 2011; 52: 1679–1683.
          5. Kim SE, Kim DY, Lee DS, et al.. Absent of faint renal uptake in bone scan etiology and significance in metastatic bone disease. Clin Nucl Med. 1991; 16: 545–549.
            6. Hain SF, Fogelman I. Nuclear medicine studies in metabolic bone disease. Semin Muskuloskelet Radiol. 2002; 6: 323–329.
              7. Kim DW, Kim CG, Park SA, et al.. Metabolic super scan in 18F-FDG PET/CT imaging. J Korean Med Sci. 2010; 25: 1256–1257.
                8. Liu RS, Chu YK, Chu LS, et al.. Superscan in patients with nasopharyngeal carcinoma. Clin Nucl Med. 1996; 21: 302–306.

                  neuroendocrine tumor; 68Ga-DOTANOC; PET/CT; superscan

                  © 2012 Lippincott Williams & Wilkins, Inc.